

## THURSDAY, OCTOBER 17

6:30 am – 6:00 pm	Registration & Information • Seaport Foyer
7:00 am – 7:45 am	BREAKFAST • Industry Sponsored Product Theater • Seaport Ballroom FG
<b>SESSION 1: PROSTATE IMAGING, SAMPLING AND SPACING</b>	
8:00 am	Welcome - <i>Arvin K. George, MD</i>
8:05 am	PIRADS V2.1 - What a Urologist Needs to Know? <i>Sadhna Verma, MD</i>
8:25 am	Can Imaging Replace Prostate Biopsy - Primary Detection, Active Surveillance and Recurrent PCa? <i>Veeru Kasivisvanathan, MBBS, PhD, FRCS</i>
8:40 am	Discussion
8:50 am	PET Scanning in Primary Detection of Prostate Cancer <i>Steven Rowe, MD</i>
9:05 am	PSMA PET for Preoperative Planning of Prostate Cancer: Nodes, Nerves and Margins <i>James Wysock, MD</i>
9:15 am	Discussion
9:25 am	Transperineal vs Transrectal Biopsy Clinical Trials: Mo' data Mo' Problems <i>Arvin K. George, MD</i>
9:40 am	Point Counterpoint: Risk Stratification for Biopsy MRI: <i>Peter A. Pinto, MD</i> Biomarkers: <i>Juan Javier-DesLoges, MD</i>
9:55 am	Rectal Spacer <i>Abhinav Sidana, MD, MPH</i>
10:05 am - 10:35 am	BREAK WITH EXHIBITORS • Seaport Ballroom ABC
<b>SESSION 2: ARTIFICIAL INTELLIGENCE</b>	
10:35 am	Introduction to AI in Healthcare <i>Giovanni Cacciamani, MD, MSc</i>
10:55 am	AI and Prostate Imaging and Biopsy <i>Baris Turkbey, MD</i>
11:15 am	AI and Treatment Planning for Prostate Cancer <i>Andre Abreu, MD</i>
11:30 am	Pragmatic Applications of AI in Urology Practice <i>Arun Rai, MD</i>
11:45 am	Panel Discussion: Artificial Intelligence in Prostate Cancer Moderator <i>Giovanni Cacciamani, MD, MSc</i> Panelists <i>Andre Abreu, MD, Baris Turkbey, MD, Arun Rai, MD</i>
12:15 pm – 1:15 pm	LUNCH • Industry Sponsored Product Theater • Seaport Ballroom FG
<b>1:15 pm – 5:45 pm ADVANCED PROSTATE CANCER MASTERCLASS • TICKETED SESSION</b>	
1:15 pm	Course Introduction: Description of Terminology and Review of Guidelines <i>Natalie Reizine, MD</i>
1:35 pm	Genetic Testing in Prostate Cancer Management <i>Abhinav Sidana, MD, MPH</i>
1:50 pm	Optimal Management of Biochemically Recurrent Nonmetastatic Prostate Cancer <i>Aaron Berger, MD</i>
2:00 pm	Discussion
2:10 pm	Metastatic Castrate Sensitive Prostate Cancer <i>Rana McKay, MD</i>
2:30 pm	SBRT for Mets: Rationale and Evidence <i>Daniel Song, MD</i>
2:40 pm	Panel Discussion: Local Prostate Therapy for Metastatic Prostate Cancer Panelists <i>Natalie Reizine, MD, Abhinav Sidana, MD, MPH, Aaron Berger, MD, Rana McKay, MD, Daniel Song, MD, Steven Rowe, MD</i>
3:10 pm - 3:40 pm	BREAK WITH EXHIBITORS • Seaport Ballroom ABC

## THURSDAY, OCTOBER 17 *continued*

3:40 pm	Urologist Led Advanced Prostate Cancer Practice: Tips, Tricks and Pitfalls <i>Aaron Berger, MD</i>
4:00 pm	Metastatic Castrate Resistant Prostate Cancer- Immunotherapy and Parp Inhibitors <i>Alan Tan, MD</i>
4:20 pm	Discussion
4:30 pm	Challenging Cases <i>Natalie Reizine, MD, Alan Tan, MD</i>
5:10 pm	Radiopharmaceuticals in Advanced Prostate Cancer <i>Steven Rowe, MD</i>
5:30 pm	Discussion
5:40 pm	Conclusion - <i>Natalie Reizine, MD</i>

## FRIDAY, OCTOBER 18

6:30 am – 6:00 pm	<b>Registration &amp; Information</b> • Seaport Foyer
7:00 am – 7:45 am	<b>BREAKFAST • Industry Sponsored Product Theater</b> • Seaport Ballroom FG
<b>*HANDS-ON COURSE I • STATE-OF-THE-ART BPH MANAGEMENT</b>	
8:00 am	Welcome & Introduction <i>John Michael DiBianco, MD</i>
8:05 am	Surgical BPH: 2024 Updates and Where Are We Going <i>Nicole Miller, MD</i>
8:15 am	Office BPH: 2024: Updates and Where Are We Going <i>Kevin Zorn, MD</i>
<b>PART 1 • Prostate Cancer Considerations Before and After BPH</b>	
8:25 am	Elevated PSA and Obstructive LUTS <i>Bilal Chughtai, MD</i>
8:35 am	Obstructive LUTS and Known Prostate Cancer <i>Kevin Zorn, MD</i>
8:45 am	Prostate Cancer after BPH Treatment <i>Ilya Sobol, MD</i>
8:55 am	Discussion
<b>PART 2 • Case Scenarios • Case: 59M, 65 mL, High Volume GG1</b>	
9:00 am	Is There a Role for UroLift? <i>Amin Herati, MD</i>
9:10 am	Is There a Role for Temporary Urethral Stents? <i>Karla Witzke, MD</i>
9:20 am	What is the Role of HoLEP? <i>Nicole Miller, MD</i>
9:30 am	Discussion
<b>PART 3 • Current and Future BPH Therapy</b>	
9:35 am	Aquablation: How I Do It Now <i>Kevin Zorn, MD</i>
9:40 am	Optilume BPH: How I Do It Now <i>Bilal Chughtai, MD</i>
9:45 am	HoLEP: How I Did It and How I Do It Now <i>Nicole Miller, MD</i>
9:50 am	Discussion
10:00 am – 10:30 am	<b>BREAK WITH EXHIBITORS</b> • Seaport Ballroom ABC

## FRIDAY, OCTOBER 18 *continued*

*BPH LIVE HANDS-ON LAB* • Seaport Ballroom H	
10:30 am – 12:00 pm	Live Hands-On Training* (Details to Come)
12:00 pm - 1:00 pm	LUNCH • Industry Sponsored Product Theater • Seaport Ballroom FG
SESSION 3: INTRODUCTION TO FOCAL THERAPY	
1:00 pm	The Changing Landscape of Focal Therapy for Prostate Cancer <i>Herbert Lepor, MD</i>
1:20 pm	Patient Selection: How to Pick a Focal Therapy Candidate? <i>Derek Lomas, MD</i>
1:35 pm	Discussion
1:45 pm	Energy Selection: Ablative Technologies for Focal Therapy <i>Andre Abreu, MD</i>
2:05 pm	Point Counterpoint: Is Focal Therapy Ready for Prime Time? Yes <i>Ruben Olivares, MD</i> No <i>Michael Rothberg, MD</i>
2:20 pm	Panel Discussion: Patient and Treatment Selection Moderator <i>Abhinav Sidana, MD, MPH</i> Panelists <i>Andre Abreu, MD, Herbert Lepor, MD, Derek Lomas, MD, Ruben Olivares, MD, Michael Rothberg, MD</i>
3:00 pm - 3:30 pm	BREAK WITH EXHIBITORS • Seaport Ballroom ABC
SESSION 4: OUTCOMES AND SURVEILLANCE OF FOCAL THERAPY	
3:30 pm	Outcomes of Recent Clinical Trials for Focal Therapy <i>Derek Lomas, MD</i>
3:50 pm	Optimal Surveillance Algorithm for Focal Therapy <i>Herbert Lepor, MD</i>
4:00 pm	Interpretation of Post Focal Therapy Imaging: Target and Pifab <i>Sadhna Verma, MD</i>
4:20 pm	Discussion
4:30 pm - 5:30 pm	BALLOON DEBATE: FOCAL FAILURE Moderator <i>Abhinav Sidana, MD, MPH</i>
	Focal Prostate Ablation <i>Amir Lebastchi, MD</i> Whole Gland Prostate Ablation <i>Aaron Katz, MD</i> Watchful Waiting/Active Surveillance <i>Arvin K. George, MD</i> Radiation Therapy <i>Daniel Song, MD</i> Radical Prostatectomy <i>Peter A. Pinto, MD</i>
5:30 pm – 6:00 pm	POSTER SESSION RECEPTION • Seaport Foyer
Poster 01	Robot Assisted Focal Ablation (RAFA) Using Cryotherapy for Prostate Cancer: Initial Experience <i>Louis S. Liou</i>
Poster 02	Augmented Triphasic Visualization of Rezum BPH Treatment in the OR and Office <i>Louis S. Liou</i>
Poster 03	Early Outcomes for Office Based Targeted Laser Ablation for Prostate Cancer Based on NCCN Risk Stratification <i>Sijo J. Parekattil, MD</i>
Poster 04	Role of Confirmatory Transperineal Mapping Biopsy in Men with Localized Prostate Cancer eligible for Partial Gland Ablation using High Intensity Focused Ultrasound <i>Wan Song, MD, PhD</i>
Poster 05	Detection of In-field Clinically-significant Prostate Cancer Recurrence Through the Use of the Prostate Imaging After Focal Ablation (PI-FAB) Score for Post-treatment Prostate Magnetic Resonance Imaging <i>Thomas Frye, DO</i>



## SATURDAY, OCTOBER 19

<b>Poster 06</b>	Retrospective Analysis of MRI-Guided Transurethral Ultrasound Ablation (TULSA) in Men with Recurrent prostate cancer <i>Joseph J. Busch</i>
<b>Poster 08</b>	Head-to-head Comparison of Biparametric versus Multiparametric MRI Sensitivity for Prostate Cancer Diagnosis in 3123 Patients: A Systematic Review and Meta-Analysis <i>Carlos A. Garcia Becerra, MD</i>
<b>Poster 09</b>	Our Initial Experience of Focal and Hemiablation with High Intensity Focused Ultrasound (HIFU) of Unilateral Localized Prostate Cancer: First Indian Experience <i>Yuvaraja Thyavihally</i>
<b>Poster 10</b>	Experience with Focal Therapy in a Large Urban Community Hospital <i>Christopher Edwards, MD</i>
<b>Poster 11</b>	Focal HDR Brachytherapy for Prostate Cancer: Minimizing Side Effects and with Effective Local Control <i>Ida Danesh</i>
<b>Poster 12</b>	Preliminary Medium-Term outcomes of Histoblast, a novel HIFU technique for Benign Prostatic Hyperplasia Treatment <i>Carlos M. Garcia Gutierrez, MD</i>
<b>Poster 13</b>	Salvage Cryoablation for Radiorecurrent Prostate Cancer: A 19-year Single Institution Experience <i>Kit Yuen, MD</i>
<b>Poster 14</b>	Performance of an AI-assisted Prostate Segmentation Module for MRI-guided Transurethral Ultrasound (TULSA) Treatment Planning: Multi-reader Multi-case Study <i>Sandeep Arora</i>
<b>Poster 15</b>	Artificial Intelligence Prostate Segmentation Integrated into Treatment Planning Software for MRI-guided Transurethral Ultrasound Ablation (TULSA): Initial Real-world Experience <i>Joseph J. Busch</i>
<b>Poster 16</b>	Transperineal Prostate Biopsy – prognostic Factors for No Prostate Tissue in Biopsy Cores <i>David Nusbaum, MD</i>
<b>Poster 17</b>	Incidence of Ideal Candidates for Focal Therapy in the MRI-Era <i>Jae Woong Jang</i>
<b>Poster 20</b>	Clinical Implications of Outpatient, Transrectal, MRI-Guided Laser Focal Therapy of Localized Prostate Cancer in an HIV Positive Patient:A Case Study <i>Bernadette M. Greenwood</i>
<b>Poster 21</b>	Clinically Significant Prostate Cancer Detection by Transperineal vs. Transrectal Magnetic Resonance Imaging Fusion Targeted Biopsy: Performance Among Possible Focal Therapy Candidates <i>Adam Lin</i>
<b>Poster 22</b>	MRI-Visible Prostate Cancer and Its Implications for Pathological Progression During Active Surveillance <i>Andre Luis Abreu</i>
<b>Poster 23</b>	Prostate Cancer Index Lesion Reclassification Artificial Intelligence: A Novel Lightweight Machine Learning for Biparametric MRI <i>Andre Luis Abreu</i>
<b>Poster 24</b>	PIRADS Lesions in Patients on Prostate Cancer Active Surveillance are Associated with Intermediate-risk Pathology and Rarely Harbor High-risk Disease <i>Ashley Vaughan</i>
<b>Poster 25</b>	Performance of mpMRI in the Detection of Clinically Significant Residual or Recurrent Cancer After Focal Therapy for Prostate Cancer <i>Simon Han</i>
<b>Poster 26</b>	Single Surgeon Experience with Procept Aquabeam Aquablation of the Prostate for Men with BPH: Five-Year Experience <i>Ali Kasraeian, MD, MHA, FACS</i>
<b>Poster 27</b>	Role of Prostate MR in the Performance and Surveillance of MR Guided Focal HDR Brachytherapy <i>Jorge Abreu-Gomez</i>
<b>Poster 28</b>	A Comparative Analysis Between the Conventional Posterior Reconstruction Technique and a Novel Technique Pioneered by Our Institution During Robot-assisted Radical Prostatectomy <i>Akinyemi Olalekan Samuel</i>

**NETWORKING RECEPTION**

**5:30 PM – 7:00 PM**

SEAPORT BALLROOM ABC

**SATURDAY, OCTOBER 19**

6:45 am – 4:30 pm	Registration & Information • Seaport Foyer
7:00 am – 8:00 am	BREAKFAST • Industry Sponsored Product Theater • Seaport Ballroom FG
<b>SESSION 5: FOCAL THERAPY CHALLENGES AND CASE DISCUSSIONS</b>	
8:00 am	Results of the PRIME Trial: Biparametric Versus Multiparametric MRI for Prostate Cancer Detection - Implications for Focal Therapy <i>Veeru Kasivisvanathan, MBBS, PhD, FRCS</i>
8:20 am	Complications of Focal Therapy - Risk Factors, Timepoints, Management <i>Amir Lebastchi, MD</i>
8:40 am	Mechanisms and Management of Recurrences <i>Abhinav Sidana, MD, MPH</i>
9:00 am	Case Discussions <b>Moderator</b> <i>Arvin K. George, MD</i> <b>Panelists</b> <i>Julien Anract, MD, Jonathan Fainberg, MD, MPH, Amir Lebastchi, MD, Abhinav Sidana, MD, MPH</i>
9:40 am -10:10 am	<b>KEYNOTE LECTURE • Introduction of Disruptive Technologies: The Lessons From the Minimally Invasive Surgery</b> <i>Ralph Clayman, MD</i>
10:10 am - 10:40 am	BREAK WITH EXHIBITORS • Seaport Ballroom ABC
<b>*LIVE HANDS-ON COURSE II • Seaport Ballroom H</b> <b>CONCURRENT SESSIONS • TRANSPERINEAL PROSTATE BIOPSY &amp; FUSION GUIDED ABLATION</b>	
10:40 am - 12:00 pm	<b>Hands-On Transperineal Prostate Biopsy &amp; Fusion Guided Ablation</b> (Details to Come)
12:00 pm - 1:00 pm	LUNCH • Industry Sponsored Product Theater • Seaport Ballroom FG
<b>*LIVE HANDS-ON COURSE III • Seaport Ballroom H</b> <b>CONCURRENT SESSIONS • TRANSPERINEAL PROSTATE BIOPSY &amp; FUSION GUIDED ABLATION</b>	
1:00 pm - 2:20 pm	<b>Hands-On Transperineal Prostate Biopsy &amp; Fusion Guided Ablation</b> (Details to Come)
2:20 pm - 2:30 pm	BREAK WITH EXHIBITORS • Seaport Ballroom ABC

**SATURDAY, OCTOBER 19** *continued*

2:30 pm - 2:45 pm	<b>Oral Abstract Presentations</b> Moderator <i>Michael Rothberg, MD</i>
2:30 pm	Oncological and Functional Outcomes Post Focal Low-Dose-Rate Brachytherapy for Low-Intermediate Risk Prostate Cancer – Results from Australia’s LIBERATE Registry <i>Mohammadmehdi Adhami, MD</i>
2:35 pm	Spatial Characterization and AI-Driven Prevention of Residual Cancer Following Focal Therapy <i>Preston Sprenkle, MD</i>
2:40 pm	Best Clinical Practices for Transperineal Prostate Biopsy: Results from an International Delphi Consensus. <i>Andre Luis Abreu, MD</i>
2:45 pm	SV Recurrences After Radiation: Is Ablation Feasible and Safe? <i>Aaron Katz, MD</i>
2:55 pm	GG4 in Elderly Patients: Is Focal Still an Undertreatment? (Watchful Waiting 2.0) <i>Jonathan Fainberg, MD, MPH</i>
3:05 pm	Discussion
<b>SESSION 6: CONTROVERSIES IN PROSTATE CANCER</b>	
3:10 pm	Diet and Prostate Cancer: What We Need to Know to Tell our Patients? <i>Stacy Loeb, MD</i>
3:25 pm	Role of Whole Gland Ablation in Prostate Cancer <i>James Wysock, MD</i>
3:40 pm	Starting a Transperineal Prostate Biopsy Program: Cost Effective Strategy for Implementation <i>Richard Wu, MD</i>
3:55 pm	CAPTAIN: A Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation of the Prostate versus Radical Prostatectomy <i>Xiaosong Meng, MD, PhD</i>
4:05 pm	Conclusion <i>Abhinav Sidana, MD, MPH</i>